Debates on the impact of CHEK2 pathogenic mutations on breast cancer risk are ongoing, with emerging data to classify pathogenic mutations of CHEK2 in moderate to low-penetrant variants [32]. This evidence concerns the gene CHEK2 and breast carcinoma.